Patient cohort survival outcomes. (A) Two-year OS was 55%, and there was no significant difference in OS based upon disease type (AML, MDS, or CML). (B) There was a statistically significant (P = .0010) difference in OS based upon disease status at time of SCT (25% vs 65%, not in CR/CP vs CR/CP). (C-D) There were no significant differences in OS based upon conditioning type (myeloablative conditioning [MAC] or RIC) or donor source (MRD or MUD).